Jane E Schreiber1, Shawna L Palmer1, Heather M Conklin1, Donald J Mabbott1, Michelle A Swain1, Melanie J Bonner1, Mary L Chapieski1, Lu Huang1, Hui Zhang1, Amar Gajjar1. 1. Department of Psychology, Department of Biostatistics, and Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA; Department of Psychology, The Hospital for Sick Children, Toronto, Ontario, Canada; Lady Cilento Children's Hospital, South Brisbane, Queensland, Australia; Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA; Department of Pediatric Medicine, Texas Children's Hospital, Houston, Texas, USA.
Abstract
BACKGROUND: Patients treated for medulloblastoma who experience posterior fossa syndrome (PFS) demonstrate increased risk for neurocognitive impairment at one year post diagnosis. The aim of the study was to examine longitudinal trajectories of neuropsychological outcomes in patients who experienced PFS compared with patients who did not. METHODS: Participants were 36 patients (22 males) who experienced PFS and 36 comparison patients (21 males) who were matched on age at diagnosis and treatment exposure but did not experience PFS. All patients underwent serial evaluation of neurocognitive functioning spanning 1 to 5 years post diagnosis. RESULTS: The PFS group demonstrated lower estimated mean scores at 1, 3, and 5 years post diagnosis on measures of general intellectual ability, processing speed, broad attention, working memory, and spatial relations compared with the non-PFS group. The PFS group exhibited estimated mean scores that were at least one standard deviation below the mean for intellectual ability, processing speed, and broad attention across all time points and for working memory by 5 years post diagnosis. Processing speed was stable over time. Attention and working memory declined over time. Despite some change over time, caregiver ratings of executive function and behavior problem symptoms remained within the average range. CONCLUSION: Compared with patients who do not experience PFS, patients who experience PFS exhibit greater neurocognitive impairment, show little recovery over time, and decline further in some domains. Findings highlight the particularly high risk for long-term neurocognitive problems in patients who experience PFS and the need for close follow-up and intervention.
BACKGROUND: Patients treated for medulloblastoma who experience posterior fossa syndrome (PFS) demonstrate increased risk for neurocognitive impairment at one year post diagnosis. The aim of the study was to examine longitudinal trajectories of neuropsychological outcomes in patients who experienced PFS compared with patients who did not. METHODS: Participants were 36 patients (22 males) who experienced PFS and 36 comparison patients (21 males) who were matched on age at diagnosis and treatment exposure but did not experience PFS. All patients underwent serial evaluation of neurocognitive functioning spanning 1 to 5 years post diagnosis. RESULTS: The PFS group demonstrated lower estimated mean scores at 1, 3, and 5 years post diagnosis on measures of general intellectual ability, processing speed, broad attention, working memory, and spatial relations compared with the non-PFS group. The PFS group exhibited estimated mean scores that were at least one standard deviation below the mean for intellectual ability, processing speed, and broad attention across all time points and for working memory by 5 years post diagnosis. Processing speed was stable over time. Attention and working memory declined over time. Despite some change over time, caregiver ratings of executive function and behavior problem symptoms remained within the average range. CONCLUSION: Compared with patients who do not experience PFS, patients who experience PFS exhibit greater neurocognitive impairment, show little recovery over time, and decline further in some domains. Findings highlight the particularly high risk for long-term neurocognitive problems in patients who experience PFS and the need for close follow-up and intervention.
Authors: Marieke A de Ruiter; Rosa van Mourik; Antoinette Y N Schouten-van Meeteren; Martha A Grootenhuis; Jaap Oosterlaan Journal: Dev Med Child Neurol Date: 2012-11-15 Impact factor: 5.449
Authors: R K Mulhern; S L Palmer; W E Reddick; J O Glass; L E Kun; J Taylor; J Langston; A Gajjar Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Shawna L Palmer; Tim Hassall; Karen Evankovich; Donald J Mabbott; Melanie Bonner; Cinzia Deluca; Richard Cohn; Michael J Fisher; E Brannon Morris; Alberto Broniscer; Amar Gajjar Journal: Neuro Oncol Date: 2010-08-16 Impact factor: 12.300
Authors: Kristen E Robinson; Claire E Fraley; Matthew M Pearson; John F Kuttesch; Bruce E Compas Journal: J Int Neuropsychol Soc Date: 2012-10-25 Impact factor: 2.892
Authors: Mariam P Korah; Natia Esiashvili; Claire M Mazewski; Roger J Hudgins; Mourad Tighiouart; Anna J Janss; Frederick P Schwaibold; Ian R Crocker; Walter J Curran; Robert B Marcus Journal: Int J Radiat Oncol Biol Phys Date: 2009-08-19 Impact factor: 7.038
Authors: Hyo Jung De Smet; Hanne Baillieux; Peggy Wackenier; Mania De Praeter; Sebastiaan Engelborghs; Philippe F Paquier; Peter P De Deyn; Peter Mariën Journal: Neuropsychology Date: 2009-11 Impact factor: 3.295
Authors: Iska Moxon-Emre; Eric Bouffet; Michael D Taylor; Normand Laperriere; Nadia Scantlebury; Nicole Law; Brenda J Spiegler; David Malkin; Laura Janzen; Donald Mabbott Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Nicole Law; Mark Greenberg; Eric Bouffet; Michael D Taylor; Suzanne Laughlin; Douglas Strother; Christopher Fryer; Dina McConnell; Juliette Hukin; Caelyn Kaise; Frank Wang; Donald J Mabbott Journal: Neuro Oncol Date: 2012-09-05 Impact factor: 12.300
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Heather M Conklin; Murali Chintagumpala; Eric Bouffet; Donald Mabbott Journal: J Clin Oncol Date: 2019-11-27 Impact factor: 44.544
Authors: Julie A Grieco; Annah N Abrams; Casey L Evans; Torunn I Yock; Margaret B Pulsifer Journal: Childs Nerv Syst Date: 2019-07-19 Impact factor: 1.475
Authors: Molly E Wickenhauser; Raja B Khan; Darcy Raches; Jason M Ashford; Giles W Robinson; Kathryn M Russell; Heather M Conklin Journal: Pediatr Neurol Date: 2019-11-29 Impact factor: 3.372
Authors: Lisa S Kahalley; M Douglas Ris; Anita Mahajan; M Fatih Okcu; Murali Chintagumpala; Arnold C Paulino; William E Whitehead; Charles G Minard; Heather H Stancel; Jessica Orobio; Judy J Xue; Emily A Warren; David R Grosshans Journal: Neuro Oncol Date: 2019-06-10 Impact factor: 12.300
Authors: Molly E Wickenhauser; Raja B Khan; Darcy Raches; Jason M Ashford; Kathryn M W Russell; Kristin Lyons; Giles W Robinson; Amar Gajjar; Paul Klimo; Heather M Conklin Journal: J Neurooncol Date: 2022-04-05 Impact factor: 4.130
Authors: Lisa M Jacola; Doralina L Anghelescu; Lacey Hall; Kathryn Russell; Hui Zhang; Fang Wang; Joanna B Peters; Michael Rossi; Jane E Schreiber; Amar Gajjar Journal: J Pediatr Date: 2020-06-09 Impact factor: 4.406
Authors: Mary C Baron Nelson; Sharon H O'Neil; Jeffrey Tanedo; Sofia Dhanani; Jemily Malvar; Christopher Nuñez; Marvin D Nelson; Benita Tamrazi; Jonathan L Finlay; Vidya Rajagopalan; Natasha Lepore Journal: Pediatr Blood Cancer Date: 2020-11-29 Impact factor: 3.167